Neurocrine Biosciences (NBIX) Assets (2010 - 2026)
Neurocrine Biosciences' Assets was $5.36 billion in Q2 2026, up 37.8% from $3.89 billion a year earlier and up 9.2% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Assets (2010 - 2026) Analysis & Trends
At the end of FY2025, Assets at Neurocrine Biosciences came in at $4.63 billion, up 24.5% from FY2024.
- Assets has now increased for nine consecutive years, with a five-year compound annual growth rate of 21.7% (FY2020 to FY2025).
- In earlier years, Assets was $3.72 billion in FY2024 (+14.4%), $3.25 billion in FY2023 (+37.3%), $2.37 billion in FY2022 (+14.3%) and $2.07 billion in FY2021 (+19.5%).
- The Q2 2026 figure marks the highest quarterly Assets in data going back to Q4 2010.
- Compared with a year earlier, Assets has increased for 37 straight quarters, with growth averaging 22.3% over the last eight quarters.
- Across the past five years, year-over-year growth in Assets ran from 2.5% in Q2 2022 to 47.1% in Q1 2024.
- Per Business Quant data, NBIX's Assets in the three quarters before Q2 2026 was $4.91 billion (Q1 2026), $4.63 billion (Q4 2025) and $4.27 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Neurocrine Biosciences | 14.41 Bn | 10.11 Bn | 935.80 Mn | 5.36 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.36 Bn |
| Mar 31, 2026 | 4.91 Bn |
| Dec 31, 2025 | 4.63 Bn |
| Sep 30, 2025 | 4.27 Bn |
| Jun 30, 2025 | 3.89 Bn |
| Mar 31, 2025 | 3.69 Bn |
| Dec 31, 2024 | 3.72 Bn |
| Sep 30, 2024 | 3.54 Bn |
| Jun 30, 2024 | 3.31 Bn |
| Mar 31, 2024 | 3.47 Bn |
| Dec 31, 2023 | 3.25 Bn |
| Sep 30, 2023 | 2.85 Bn |
| Jun 30, 2023 | 2.61 Bn |
| Mar 31, 2023 | 2.36 Bn |
| Dec 31, 2022 | 2.37 Bn |
| Sep 30, 2022 | 2.14 Bn |
| Jun 30, 2022 | 2.01 Bn |
| Mar 31, 2022 | 2.14 Bn |
| Dec 31, 2021 | 2.07 Bn |
| Sep 30, 2021 | 2.02 Bn |
API Access
Neurocrine Biosciences Assets API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=assets&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "assets", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=assets&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();